Kevin Groen

Kevin Groen

Auto-generated profile, based on publicly available information

Kevin Groen

Institute of Medical Virology, University of Zurich 1 , Zurich

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
SFSonja Fernbach
Sonja Fernbach
NMNina K. Mair
Nina K. Mair
IAIrene A. Abela
Irene A. Abela
KGKevin Groen
Kevin Groen
RKRoger Kuratli
Roger Kuratli
SYSabine Yerly
Sabine Yerly
Autoantibodies neutralizing type I interferons (IFN-Is) can underlie infection severity. Here, we trace the development of these autoantibodies at high-resolution using longitudinal samples from 1,876 well-treated individuals living with HIV over a 35-year period. Similar to general populations, ∼1.9% of individuals acquired anti-IFN-I autoantibodies as they aged (median onset ∼63 years). Once detected, anti-IFN-I autoantibodies persisted lifelong, and titers increased over decades. Individuals developed distinct neutralizing and non-neutralizing autoantibody repertoires at discrete times that selectively targeted combinations of IFNα, IFNβ, and IFNω. Emergence of neutralizing anti-IFNα autoantibodies correlated with reduced baseline IFN-stimulated gene levels and was associated with subsequent susceptibility to severe COVID-19 several years later. Retrospective measurements revealed enrichment of pre-existing autoreactivity against other autoantigens in individuals who later developed anti-IFN-I autoantibodies, and there was evidence for prior viral infections or increased IFN at the time of anti-IFN-I autoantibody triggering. These analyses suggest that age-related loss of self-tolerance prior to IFN-I immune-triggering poses a risk of developing lifelong functional IFN-I deficiency.

20 March 2025 in Journal of Experimental Medicine
Verified
Journal Article
Open access
KGKevin Groen
Kevin Groen
RKRoger Kuratli
Roger Kuratli
JEJannik Enkelmann
Jannik Enkelmann
SFSonja Fernbach
Sonja Fernbach
PWPedro D Wendel-Garcia
Pedro D Wendel-Garcia
BHBenjamin Hale
Benjamin Hale
Autoantibodies neutralizing type I interferons (IFN-Is; IFNα or IFNω) exacerbate severe viral disease, but specific treatments are unavailable. With footprint profiling, we delineate two dominant IFN-I faces commonly recognized by neutralizing IFN-I autoantibody–containing plasmas from aged individuals with HIV-1 and from individuals with severe COVID-19. These faces overlap with IFN-I regions independently essential for engaging the IFNAR1/IFNAR2 heterodimer, and neutralizing plasmas efficiently block the interaction of IFN-I with both receptor subunits in vitro. In contrast, non-neutralizing autoantibody–containing plasmas limit the interaction of IFN-I with only one receptor subunit and display relatively low IFN-I–binding avidities, thus likely hindering neutralizing function. Iterative engineering of signaling-inert mutant IFN-Is (simIFN-Is) retaining dominant autoantibody targets created potent decoys that prevent IFN-I neutralization by autoantibody-containing plasmas and that restore IFN-I–mediated antiviral activity. Additionally, microparticle-coupled simIFN-Is were effective at depleting IFN-I autoantibodies from plasmas, leaving antiviral antibodies unaffected. Our study reveals mechanisms of action for IFN-I autoantibodies and demonstrates a proof-of-concept strategy to alleviate pathogenic effects.

3 February 2022 in Journal of Infection
Verified
Journal Article
Closed access
CKCmhj Kivit
Cmhj Kivit
KGK Groen
K Groen
MJM Jongbloed
M Jongbloed
CLCfm Linssen
Cfm Linssen
ALA van Loo
A van Loo
DKde Kruif
de Kruif

1 September 2021 in Virus Research
Verified
Journal Article
Open access
KGKevin Groen
Kevin Groen
SNStefan van Nieuwkoop
Stefan van Nieuwkoop
TBTheo M. Bestebroer
Theo M. Bestebroer
PFPieter L. Fraaij
Pieter L. Fraaij
RFRon A.M. Fouchier
Ron A.M. Fouchier
Bernadette Van Den HoogenBernadette Van Den Hoogen
Bernadette Van Den Hoogen
Human metapneumovirus (HMPV), a member of the Pneumoviridae family, is a causative agent of respiratory illness in young children, the elderly, and immunocompromised individuals. Globally, viruses belonging to two main genetic lineages circulate, A and B, which are further divided into four genetic sublineages (A1, A2, B1, B2). Classical genotyping of HMPV is based on the sequence of the fusion (F) and attachment (G) glycoprotein genes, which are under direct antibody-mediated immune pressure. Whole genome sequencing provides more information than sequencing of subgenomic fragments and is therefore a powerful tool for studying virus evolution and disease epidemiology and for identifying transmission events and nosocomial outbreaks. Here, we report a robust method to obtain whole genome sequences for HMPV using MinION Nanopore technology. This assay is able to generate HMPV whole genome sequences from clinical specimens with good coverage of the highly variable G gene and is equally sensitive for strains of all four genetic HMPV sublineages. This method can be used for studying HMPV genetics, epidemiology, and evolutionary dynamics.

6 March 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SFSonja Fernbach
Sonja Fernbach
NMNina K. Mair
Nina K. Mair
IAIrene Alma Abela
Irene Alma Abela
KGKevin Groen
Kevin Groen
RKRoger Kuratli
Roger Kuratli
TSThe Swiss HIV Cohort Study
The Swiss HIV Cohort Study
Pre-existing autoantibodies (autoAbs) neutralizing type I interferons (IFN-Is: IFNα, IFNβ, IFNω) have recently been described as significant contributors to the severity of viral infectious diseases. Here, we explore the development and consequences of anti-IFN-I autoAbs at high-resolution using retrospective samples and data from 1876 well-treated individuals >65 years of age enrolled in the Swiss HIV Cohort Study, a nationwide, longitudinal cohort with up to 35 years of follow-up. Approximately 1.9% of individuals developed anti-IFN-I autoAbs, with a median onset age of ∼63 years (range 45-80). Once developed, anti-IFN-I autoAbs persisted for life, and generally increased in titer over years. Most individuals developed distinct neutralizing and non-neutralizing anti-IFN-I autoAb repertoires at discrete times that selectively targeted various combinations of IFNα, IFNβ, and IFNω. Longitudinal analyses further revealed that emergence of neutralizing anti-IFNα autoAbs correlated with reduced IFN-stimulated gene (ISG) levels, indicating impairment of innate immunity. Patient data review suggested that prior recorded viral infections and autoimmune history influence the likelihood of mounting anti-IFN-I autoAbs. Indeed, systematic measurements in biobanked samples revealed significant enrichment of pre-existing autoreactivity against clinically relevant autoantigens in individuals who later developed anti-IFN-I autoAbs. In this context, we describe lifelong neutralizing anti-IFNα autoAbs (and impaired innate immunity), that manifested in an individual following IFNα therapy, and who was retrospectively found to have had pre-existing autoreactivity to β2-glycoprotein-I before IFNα treatment. Our decades-spanning longitudinal analyses illuminate the development and immune implications of anti-IFN-I autoAbs in an aging population, and support a ‘two-hit’ hypothesis whereby loss of self-tolerance prior to immune-triggering with endogenous or exogenous IFN-I may pose a risk for developing late-onset, lifelong IFN-I functional deficiency.

22 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
KGKevin Groen
Kevin Groen
RKRoger Kuratli
Roger Kuratli
AVAndri Vasou
Andri Vasou
MHMichael Huber
Michael Huber
DHDavid J. Hughes
David J. Hughes
BHBenjamin Hale
Benjamin Hale
Interferons (IFNs) are a critical component of innate immune defenses and limit viral disease severity. To advance studies on IFNs and their neutralization by pathogenic autoantibodies, we generated a Renilla luciferase-based reporter cell line capable of detecting the activities of IFN-Is, IFN-II, and IFN-IIIs. The reporter cell line exhibits a 125-to 2000-fold higher sensitivity to IFNs than a commonly-used alternative biological reporter system, and allows for a rapid and simple live-cell workflow for detecting low titer amounts of neutralizing anti-IFN antibodies.